Patients with resolved hepatitis B virus (HBV) infection who are treated for hematological malignancies remain at risk for HBV reactivation. Because of conflicting studies about whether the antibody to hepatitis B surface antigen (anti-HBs) protects against reactivation in patients with resolved infection (hepatitis B surface antigen negative) receiving chemotherapy for hematological malignancies, we conducted a meta-analysis to determine if anti-HBs reduces HBV reactivation risk. We sought English-language studies through March 1, 2016, in Medline and other sources that examined reactivation in patients with resolved HBV infection receiving chemotherapy for hematologic malignancies. The absolute risks and odds ratio (OR) of reactivation with versus without anti-HBs were estimated in random-effects model meta-analyses. In 20 studies involving 1,672 patients not receiving antiviral prophylaxis, the reactivation risk was 14% (95% confidence interval [CI] 9.4%-19%) in 388 patients who had antibodies to hepatitis B core antigen only versus 5.0% (95% CI 3.0%-7.0%) in 1,284 patients who also had anti-HBs. Anti-HBs reduced reactivation risk with a pooled OR of 0.21 (95% CI 0.14-0.32) versus patients with antibody to hepatitis B core antigen only. Similar results were found when limiting the analysis to rituximab chemotherapy (OR 5 0.19, 95% CI 0.11-0.32) and lymphoma (OR 5 0.18, 95% CI 0.11-0.28). Conclusion: In patients with resolved HBV receiving chemotherapy for hematological malignancies without antiviral prophylaxis, antiHBs positivity is associated with a decreased risk of reactivation; HBV screening in this patient population should include the routine use of anti-HBs, and those who are anti-HBs-negative should receive antiviral prophylaxis. Future studies should examine the effect of anti-HBs serum titers, the potential role for booster vaccinations, and antiviral prophylaxis prior to chemotherapy in this patient population. (HEPATOLOGY 2017;66:379-388).
H
epatitis B virus (HBV) reactivation in the setting of immunosuppressive therapy, in particular chemotherapy, has garnered increasing attention (1) (2) (3) (4) (5) because reactivation can lead to hepatitis, liver failure, and death and interrupt or delay treatment. (6) The risk of reactivation depends on HBV serological status and the intensity of chemotherapeutic regimens. (1, 2, 4, 7) Those with chronic HBV infection (positive hepatitis B surface antigen [HBsAg] ) receiving rituximab-based chemotherapy or bone marrow transplantation have the highest risk of reactivation, ranging from 30% to 80% in the absence of antiviral prophylaxis.
Patients with resolved HBV infection (defined as negative HBsAg, positive antibody to hepatitis B core antigen [anti-HBc] , and positive antibody to HBsAg [anti-HBs]) and past HBV infection (defined as negative HBsAg, positive anti-HBc, and negative or unknown anti-HBs) remain at risk for reactivation, particularly when receiving rituximab-based chemotherapy with reactivation rates as high as 16%. (8) However, whether positive anti-HBs protects against reactivation remains uncertain. Previous studies have suggested that decreased anti-HBs titer level and absence of pretreatment anti-HBs are risk factors for reactivation in hematological malignancies. (9, 10) Conversely, other studies have shown a low risk of reactivation in those who are solely positive for anti-HBc but negative for anti-HBs, (11, 12) leading to recent reviews questioning the protective effects of anti-HBs for HBV reactivation. (1, 8) Given the limited and conflicting data, we conducted a systematic review and meta-analysis to quantify the overall risk of HBV reactivation in patients with resolved or past HBV infection who receive chemotherapy for hematological malignancies and then quantify reactivation in those who are positive for antiHBc with versus without anti-HBs. Of note, resolved and past HBV infection have been used interchangeably in studies and will be combined and reported as resolved HBV in the current meta-analysis.
Materials and Methods

SEARCH STRATEGY
We searched MEDLINE, Web of Science, Cochrane Central Register of Controlled Trials, and Scopus from 1965 to March 1, 2016, using three index search themes ("hepatitis B virus," "cancer chemotherapy," and "virus reactivation"; see Supporting Fig.  S1 ). The search was restricted to published papers in English. Conference abstracts and proceedings, letters to the editor, and case reports were excluded. To identify other potential studies, we also examined reference lists of review articles and previous meta-analyses and contacted authors of included studies with incomplete data. We adhered to systematic review and metaanalysis methodology consistent with the Metaanalysis of Observational Studies in Epidemiology guidelines. (13) We also developed and followed an unregistered protocol.
STUDY SELECTION
Two independent investigators (S.P. and A.S.) reviewed all citations for relevance, and discrepancies were settled through consultation with a third investigator (J.B.W.). We included published studies of patients with resolved HBV infection undergoing chemotherapy for any hematological malignancy, with or without concomitant HBV prophylaxis therapy. Resolved HBV infection was defined serologically (prior to chemotherapy initiation) as negative HBsAg and positive anti-HBc with or without anti-HBs. Studies had to report anti-HBs status to be included.
The primary outcome was HBV reactivation as defined by detectable or increase in HBV DNA levels from baseline or the reemergence of HBsAg (or HBsAg seroconversion), as specified by authors. We included randomized controlled trials (RCTs) and observational comparative studies (retrospective or prospective). Studies had to include more than 5 patients and report a minimum of 1-month follow-up results. Studies with pediatric populations (age <18 years), solid cancers, transplantation (including solid organ and bone marrow or hematopoietic stem cell), human 
DATA EXTRACTION
Data were extracted by one researcher (S.P.) and verified by another independent researcher (A.D.). Prespecified data extraction forms included study author, country, design, patient age and sex, HBV serology (including presence of HBsAg, anti-HBc, and anti-HBs), type of malignancy, chemotherapy received, antiviral prophylaxis (if any), and study follow-up period. If a study involved both solid and hematological malignancies, only the hematological malignancy data were extracted.
QUALITY ASSESSMENT
We used the Newcastle-Ottawa Scale for observational studies (14) to assess study quality. A maximum of 9 points were awarded to each study: 4 points for patient selection, 2 points for comparability between study groups through design or analysis, and 3 points for outcome assessment and adequacy of follow-up. Studies with 0 points for at least four elements in the scale were considered to be of low quality. Additionally, those studies not reporting demographic information (including patient age and sex) or total follow-up duration (all studies were followed for at least 1 month per inclusion criteria) were considered to be of low quality.
DATA SYNTHESIS AND STATISTICAL ANALYSIS
We estimated the absolute likelihood of HBV reactivation using pooled estimates of risk. Because of the low number of events, an arcsine transformation was applied to the risk estimates to stabilize the variance. (15) Both the transformed risk estimates and the odds ratios (OR) of HBV reactivation with versus HBV DNA >10-fold increase versus previous nadir; E, conversion from HBsAg-negative to HBsAg-positive. † Study included patients with prophylaxis but, given small numbers, was excluded from the analysis. ‡ Some patients had rituximab, but we were unable to determine numbers with and without anti-HBs. Abbreviations: AML, acute myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; ENT, entecavir; HBVr, HBV reactivation; IQR, interquartile range; L, lamivudine; MM, multiple myeloma; N/A, not applicable; NHL, non-Hodgkin lymphoma; NR, not reported; P, prospective cohort; Ppx, prophylaxis; R, retrospective cohort.
without anti-HBs were meta-analyzed using a random-effects model (DerSimonian and Laird). For studies reporting zero events, we added a 0.5 correction factor to calculate the OR. The I 2 statistic was used to evaluate heterogeneity between studies, with 0% to 40% considered to be low, 41% to 60% moderate, 61% to 80% substantial, and 81% to 100% considerable heterogeneity. (16) A funnel plot and the Harbord test (17) assessed the relationship between study precision and treatment effect for the primary outcome. Statistical analyses were performed with OpenMetaAnalyst (18) and the metafor package in R, version 3.2.1 (R Foundation for Statistical Computing). (19) Prespecified subgroup analyses explored differences in reactivation by rituximab-based chemotherapy, lymphoma malignancies, and geographic region. In addition, sensitivity analyses examined study design (retrospective versus prospective) and study quality.
Results
In the 2,248 citations identified through database searches, 20 original reports met eligibility criteria (Fig. 1) . Of the 19 observational studies, 11 were prospective (10, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) and eight were retrospective. (9, (30) (31) (32) (33) (34) (35) (36) One RCT compared entecavir HBV prophylaxis (before chemotherapy) versus entecavir treatment for HBV reactivation. (37) STUDY AND PATIENT CHARACTERISTICS Table 1 summarizes the baseline study characteristics. The 20 studies consisted of 1,713 patients with complete serology data for analysis (range 8-234). Of these, only 41 patients in one study received antiviral prophylaxis. (37) When reported, the median patient age across studies was 64 years (range 18-90), with 707 males and 552 females. Seventeen studies were from Asian countries, and three were from Italy. Fourteen studies examined only lymphoma, while three included other hematological malignancies, e.g., leukemia and multiple myeloma. Chemotherapeutic regimens differed across studies, with only rituximab used in 10 studies with complete HBV serologies. The definition of HBV reactivation varied, with nine studies defining it as HBV DNA levels above a cutoff (seven studies used a >10-fold increase versus previous nadir (23, 25, 28, 32, (34) (35) (36) and two studies used >10 IU/mL (21, 22) ). Four studies simply defined reactivation as detectable HBV DNA. (24, 27, 30, 37) Six studies used HBV detection with or without conversion from HBsAg-negative to HBsAg-positive. (9, 10, 20, 31, 33) One study used conversion to HBsAg positivity for reactivation. (26) Only three studies provided information on serum titers of anti-HBs. (22, 30, 31) QUALITY ASSESSMENT Based on the Newcastle-Ottawa Scale quality scale items, all studies scored well on exposure ascertainment, outcome assessment, and absence of the outcome at study onset (Supporting Table S1 ). However, because the primary purpose of these studies was to report reactivation in resolved HBV infection, demographic information was unavailable for the two cohorts with and without anti-HBs, making it difficult to assess whether selection bias affected the cohort with anti-HBc alone. For RCTs, the Cochrane Collaboration's tool for assessing risk of bias is usually used to assess study quality. In the one RCT in this meta-analysis, (37) patients were randomized for treatment (to either entecavir or control) and not based on the presence of anti-HBs. As a result, the Newcastle-Ottawa Scale was extrapolated to assess quality. Of seven low-quality studies (Table 1;  Supporting Table S1 ), five did not have both follow-up time and demographic information, (26) (27) (28) 32, 35) one had incomplete demographic information, (24) and one did not specify follow-up time. (10) 
HBV REACTIVATION IN PATIENTS WITHOUT ANTIVIRAL PROPHYLAXIS
In the 1,672 patients in 20 studies with resolved HBV infection who did not receive antiviral prophylaxis, the overall risk of reactivation was 7.2% (95% confidence interval [CI] 5.0%-10%). In 800 patients from 10 studies (9, (20) (21) (22) (23) 25, 33, 34, 36, 37) receiving rituximab chemotherapy, reactivation risk was 10% (95% CI 5.8%-16%) versus a 4.0% risk (95% CI 2.2%-6.3%) in 580 patients from eight studies (20, 24, (30) (31) (32) (34) (35) (36) receiving nonrituximab chemotherapy. In 1,142 lymphoma patients from 14 studies, (10, (21) (22) (23) 25, 27, 28, (33) (34) (35) (36) (37) reactivation occurred in 8.0% (95% CI 4.0%-11%).
In 388 patients who were only anti-HBc-positive (anti-HBs-negative) the risk of reactivation was 14% (95% CI 9.4%-19%) compared to 5.0% (95% CI 3.0%-7.0%) in 1,284 patients who also had anti-HBs. Similar results with decreased reactivation risk in antiHBs-positive patients were seen when the data were analyzed by rituximab chemotherapy, lymphoma, and geographic region (Table 2) .
A positive anti-HBs versus only anti-HBc reduced reactivation with a pooled OR of 0.21 (95% CI 0.14-0.32) (Fig. 2) . (9, 10, (20) (21) (22) (23) (24) (25) (26) (27) (28) (30) (31) (32) (33) (34) (35) (36) (37) The regression test for funnel plot asymmetry was not significant (P 5 0.84). In 800 patients from 10 studies (9, (20) (21) (22) (23) 25, 33, 34, 36, 37) receiving only rituximab-based chemotherapies, antiHBs versus only anti-HBc reduced reactivation with an OR of 0.19 (95% CI 0.11-0.31) (Fig. 3) . A similar trend was seen in 580 patients receiving nonrituximabbased therapies but did not reach statistical significance (0.46, 95% CI 0.20-1.1). In 1,142 lymphoma patients from 14 studies, (9, 10, (21) (22) (23) 25, 27, 28, (33) (34) (35) (36) (37) anti-HBs reduced reactivation with an OR of 0.18 (95% CI 0.11-0.28) (Fig. 4) versus anti-HBc only. When analyzed by geographic region, the protective effect of anti-HBs was also significant (Asia OR 5 0.22, 95% CI 0.14-0.34; Italy OR 5 0.07, 95% CI 0.01-0.54).
No heterogeneity (I 2 5 0%) was found in any of these analyses. When excluding the seven low-quality studies, the protective effect for positive anti-HBs versus only anti-HBc remained significant (OR 5 0.21, 95% CI 0. 13 
HBV REACTIVATION IN PATIENTS WITH ANTIVIRAL PROPHYLAXIS
In the only study with complete serological data for patients receiving antiviral prophylaxis, (37) 41 patients received prophylactic entecavir within 1 week before the first course of chemotherapy and continued until 3 months after chemotherapy cessation. Of the 33 patients who received entecavir and were anti-HBspositive, one reactivation event occurred (3.0%). No reactivation occurred in 8 patients who were antiHBc-positive alone.
Discussion
In patients with resolved HBV receiving chemotherapy for hematological malignancies, our analysis found that anti-HBs decreased HBV reactivation in the absence of antiviral prophylaxis, with an OR of 0.21 versus those with anti-HBc alone. Similar results were seen when the data were restricted to lymphoma patients or to those receiving only rituximab chemotherapy. Our results demonstrate very different reactivation risks in patients with and without anti-HBs and support the role of screening patients prior to chemotherapy with HBsAg, anti-HBc, and anti-HBs as currently recommended by the Centers for Disease Control and Prevention (38) and the American Association for the Study of Liver Diseases. (5) Two previous reviews have examined the role of anti-HBs in the risk of reactivation in patients with resolved HBV infection. (2, 8) One meta-analysis that examined patients receiving rituximab chemotherapy only identified three studies involving 145 patients and found a nonsignificant reduction in reactivation risk in patients with measurable anti-HBs (OR 5 0.08, P 5 0.151). (8) Similar to our results, the American Gastroenterology Association (AGA) review estimated a 4.3% risk of HBV reactivation in six studies involving 252 patients who had anti-HBs and resolved HBV. (1) However, they concluded that this risk was only "slightly lower" than the overall HBV reactivation risk in all 401 patients with resolved infection.
(2) Given these results and the absence of serum anti-HBs titer information in most studies, the AGA currently does not recommend using anti-HBs status to guide antiviral prophylaxis in patients with resolved infection. (1) In contrast to the AGA review, our meta-analysis included 20 studies and 1,672 patients. We found an overall 7.2% risk of HBV reactivation, a 10.0% risk with rituximab-based regimens, a 4.0% risk with nonrituximab chemotherapy, and an 8.0% risk in patients with lymphoma, similar to previous reports. (2, 21, 39, 40) However, in the absence of anti-HBs, the risk of reactivation increased across all groups, with the highest risk seen in rituximab chemotherapy (24%) and lymphoma (19%). This increased risk highlights two important points. First, routine screening for HBV in the setting of impending immunosuppression should include testing for anti-HBs (in conjunction with HBsAg and anti-HBc) because anti-HBs can help stratify reactivation risk. Second, patients without antiHBs and resolved HBV infection have an increased risk of reactivation and should receive antiviral prophylaxis in this setting.
The presence of anti-HBs decreased reactivation risk among all groups but did not eliminate the risk. Those that received rituximab continued to have a reactivation risk of 5.6%. Given the increased risk of reactivation associated with rituximab-based therapy, we are in agreement with current guidelines (1) that recommend HBV antiviral prophylaxis in patients receiving rituximab-based regimens regardless of anti-HBs status.
However, management of patients with resolved HBV infection receiving nonrituximab-based chemotherapy regimens remains uncertain. We did not find any studies examining the benefits of antiviral prophylaxis versus vigilant monitoring of serum liver tests and HBV DNA levels. As currently suggested by the AGA, serum anti-HBs titers in those who are anti-HBs-positive may help identify when to administer antiviral prophylaxis. (1) In one study of 29 patients with lymphoma treated with rituximab, anti-HBs titers fell significantly lower after chemotherapy. (41) None of the 10 patients with baseline anti-HBs titers >100 mIU/mL experienced HBV reactivation, but 8 of 19 patients with baseline titers <100 mIU/mL developed HBV reactivation.
Although nearly all studies in the current metaanalysis did not report anti-HBs levels, we did identify three studies measuring baseline serum anti-HBs levels prior to chemotherapy. (22, 30, 31) In 230 patients with multiple myeloma, anti-HBs-negative status was the only statistically significant risk factor associated with HBV reactivation. (31) In 24 patients with adult T-cell leukemia and lymphoma treated with mogamulizumab (an anti-CC chemokine receptor 4 monoclonal antibody), 2 of 13 patients with serum anti-HBs titers <100 mIU/mL developed reactivation, and 1 of 11 patients with higher titers developed reactivation. (30) In patients with lymphoma undergoing rituximabbased chemotherapy, undetectable anti-HBs at baseline was the only factor statistically significantly associated with HBV reactivation, with a hazard ratio of 3.51 (95% CI 1.37-8.98). (22) Given these findings, measuring serum titers of anti-HBs should be explored in future research as an additional reactivation risk predictor.
Given the important role of anti-HBs in HBV reactivation, two bone marrow transplantation studies suggest that augmenting the anti-HBs response with HBV vaccination may be beneficial. (42, 43) In a cohort of 46 patients who received allogeneic bone marrow transplants, 21 received a standard three-dose hepatitis B vaccine in the posttransplant period. Of the 25 nonvaccinated patients, 12 experienced HBV reactivation compared to none of the 21 vaccinated patients after a median follow-up period of 60 months. (42) Interestingly, even those patients who were vaccinated but remained anti-HBs-negative averted HBV reactivation. Further vaccination investigations may be warranted for patients with hematological malignancies receiving chemotherapy, especially rituximab.
The current analysis is limited to hematological malignancies. A previous review examined the risk of HBV reactivation in those with resolved HBV infection and solid tumors. (44) The reactivation risk ranged from 0.3% to 9.0% (median 3.0%) in three studies of 328 patients. Anti-HBs status was not reported in these studies to determine its role in HBV reactivation.
Our review has several limitations. First, the majority of the studies were observational, and some had missing demographic or clinical information and follow-up duration that influenced study quality. Study quality was difficult to assess with regard to selection bias and comparability between the two groups (with and without anti-HBs), and none of the studies had blinded outcome assessment. Notably, however, excluding poor-quality studies did not appreciably affect the results. Second, no studies reported clinically meaningful endpoints such as delayed chemotherapy, liver failure, need for transplantation, tumor response, and cancer-related and all cause-mortality following HBV reactivation. Anti-HBs titer levels were also unavailable in the majority of the studies. Studies also used different HBV DNA assays with various sensitivities that could have potentially affected the results of the analysis. Additionally, a large proportion of the studies were from Asia, potentially limiting the generalizability of the results to regions where the HBV prevalence is lower. Lastly, although the funnel plot asymmetry test was not significant, publication bias is still possible as studies were limited to publication in English-language journals and excluded conference proceedings.
In conclusion, in patients with resolved HBV receiving chemotherapy for hematological malignancies, our results found that the presence of anti-HBs decreased the risk of HBV reactivation. This finding supports the inclusion of anti-HBs in screening protocols prior to chemotherapy for hematological malignancy with antiviral prophylaxis for those who are anti-HBsnegative. Future studies should examine the effect of serum anti-HBs titers and the role of HBV vaccination on reactivation risk.
